retatrutide dosing clinical trial produces up to 30.3% weight loss in Phase 3 VisualAbstract: Retatrutide reduces body weight
Description
Requires medical evaluation and approval by a licensed provider
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
Rebates for this class are expected to be significant given the competitive market choices available
Acknowledgements This work was supported by grants from National Institute of Diabetes and Digestive and Kidney Diseases (R01DK121804) and National Institute of Food and Agriculture (67017-29252) Ethics declarations Competing interests The authors declare no competing interests
Cold sensitivity typically signals active metabolic changes and caloric reductionboth hallmarks of semaglutide's therapeutic effect
The research is published in Nature Medicine
